Cartesian Therapeutics, an innovative biopharmaceutical company based in Gaithersburg, MD, has taken a significant step forward in its research and innovation initiatives by appointing Professor Christopher M. Jewell, PhD/MS, as its new Chief Scientific Officer. This announcement, made on February 14, 2023, follows the appointment of Dr. Michael Singer, the previous Chief Scientific Officer, who has transitioned to serve as Chairman of the Board and Chief Strategy Officer.
A Leader in Immune Engineering
Dr. Jewell brings a wealth of expertise in immune engineering and nanotechnology, fields in which he has made substantial contributions over the past decade while serving at the University of Maryland. As the MPower Professor and Minta Martin Professor, he has successfully garnered over $25 million in funding and has authored 125 manuscripts and patents. His research has appeared in prestigious journals, including Nature, Nature Biotechnology, and Nature Materials.
Recognized Excellence
Throughout his career, Dr. Jewell has received more than 50 accolades, highlighting his excellence in scientific research and innovation. Notably, he was honored with the Presidential Early Career Award for Scientists and Engineers (PECASE), which is regarded as the highest honor bestowed upon early-career scientists in the United States. Additionally, he is an elected fellow of numerous professional societies, further underscoring his impact in the scientific community.
Translational Medicine Expertise
In addition to his academic achievements, Dr. Jewell has extensive experience in translational medicine, having spent 15 years advising various pharmaceutical companies. His tenure at the Boston Consulting Group equipped him with valuable insights into the commercialization of scientific discoveries, making him well-suited to lead Cartesian Therapeutics’ research efforts.
Vision for the Future
Murat Kalayoglu, MD, PhD, President and CEO of Cartesian, expressed his enthusiasm regarding Dr. Jewell’s appointment. He stated that Dr. Jewell’s impressive track record in discovery and innovation will not only enhance the capabilities of Cartesian’s research team but will also pave the way for the development of revolutionary RNA cell therapies aimed at treating patients with serious medical conditions.
Advancing RNA Cell Therapy
Cartesian Therapeutics is at the forefront of pioneering RNA cell therapies targeting autoimmune diseases and cancer. Their flagship product, Descartes-08, is a groundbreaking RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) currently undergoing Phase 2b clinical trials for patients suffering from generalized myasthenia gravis. The company operates a cutting-edge cGMP manufacturing facility in Gaithersburg, ensuring the highest standards in the production of its therapies.
Commitment to Innovation
With Dr. Jewell’s leadership, Cartesian Therapeutics is poised to further elevate its research initiatives and innovation in the biopharmaceutical sector. The appointment reflects the company’s ongoing commitment to developing transformative therapies that can significantly improve patient outcomes.
Conclusion
The strategic appointment of Dr. Christopher Jewell as Chief Scientific Officer marks a pivotal moment for Cartesian Therapeutics. His extensive experience and proven track record in research and development promise to enhance the company’s mission of advancing RNA cell therapies. With a focus on innovation and patient care, Cartesian is well-positioned to lead the way in the evolving landscape of biopharmaceuticals.
- Cartesian Therapeutics appoints Dr. Christopher Jewell as Chief Scientific Officer.
- Dr. Jewell has an extensive background in immune engineering and nanotechnology.
- Cartesian is developing advanced RNA cell therapies for autoimmune diseases and cancer.
- The company’s lead asset, Descartes-08, is currently in Phase 2b clinical trials.
- This leadership change signifies a strong commitment to research and innovation in the biopharmaceutical industry.
Read more → fischellinstitute.umd.edu